WASHINGTON — Under a new proposal, the Medicare program would pay for expensive new cancer therapies known as CAR-T for patients across the country.

The Centers for Medicare and Medicaid Services on Friday released a so-called national coverage determination for the therapies that lays out exactly when, and for whom, Medicare will cover a given drug. The proposal specifies that Medicare will cover all FDA-approved CAR-T therapies as long as data is collected about how the patients fare, which could inform the government’s policies about paying for the therapy in the future.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • What may be lost in this is the likelihood that CAR T will become a 3rd line therapy and generally replace the need for Bone Marrow Transplant. The latter is quite expensive and has overall poor survival. In patients failing on this, you will see repeated transplants and multiple admissions for infections. Screening and getting Donors also adds to the costs, as does follow up studies.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy